Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PTN

Palatin Technologies Inc

Feb 18 • 04:00PM ET

19.35

+1.76 10.01 %

Healthcare • Biotechnology • USA • AMEX

Feb 17, 9:16 AMPalatin Technologies posts fiscal Q4 2025 results (non-GAAP EPS -$2.86, revenue $25k; EPS miss, revenue beat) and, in a fiscal Q2 2026 update, reports a $7.3M net loss, $14.5M cash with runway past March 2027, and plans to advance MC4R-based obesity candidates PL7737 and a long-acting peptide into 2026 clinical trials.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.13	Insider Own	9.51%	Shs Outstand	1.76M	Perf Week	14.77%
Market Cap	32.95M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	-0.35%	Shs Float	1.54M	Perf Month	10.26%
Enterprise Value	18.82M	PEG	-	EPS next Q	-1.24	Inst Own	30.47%	Short Float	13.06%	Perf Quarter	79.17%
Income	-9.63M	P/S	3.68	EPS this Y	86.82%	Inst Trans	38.54%	Short Ratio	3.24	Perf Half Y	121.14%
Sales	8.96M	P/B	2.97	EPS next Y	47.29%	ROA	-86.59%	Short Interest	0.20M	Perf YTD	25.81%
Book/sh	6.53	P/C	2.28	EPS next 5Y	54.06%	ROE	-378.67%	52W High	54.00 -64.17%	Perf Year	-62.43%
Cash/sh	8.50	P/FCF	-	EPS past 3/5Y	44.66% 23.09%	ROIC	-83.03%	52W Low	1.75 1005.71%	Perf 3Y	-87.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-4.89%	Volatility	9.76% 11.36%	Perf 5Y	-98.29%
Dividend TTM	-	EV/Sales	2.10	EPS Y/Y TTM	87.54%	Oper. Margin	-139.45%	ATR (14)	1.92	Perf 10Y	-96.84%
Dividend Ex-Date	-	Quick Ratio	2.76	Sales Y/Y TTM	2461.02%	Profit Margin	-107.41%	RSI (14)	61.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	51.67%	SMA20	16.47%	Beta	0.43	Target Price	54.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	6.97%	Rel Volume	0.48	Prev Close	17.59
Employees	29	LT Debt/Eq	0.01	Earnings	Feb 17 BMO	SMA200	76.07%	Avg Volume	62.03K	Price	19.35
IPO	Oct 28, 1993	Option/Short	No / Yes	EPS/Sales Surpr.	-21.53% 364.00%	Trades		Volume	29,735	Change	10.01%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

Feb-17-26 06:00PM	Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +10.01%
07:30AM	Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your FINVIZ experience